Please assess the completion status of the following clinical trial:

Trial Title: TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Type 2 diabetes~* Age ≥30 and ≤80~* Currently treated with two classes of oral glucose-lowering therapy (given either as separate or combined medications), that do not include a DPP4-inhibitor, a SGLT2-inhibitor or a thiazolidinedione.~* Diabetes duration ≥12months~* No change in diabetes treatment (new treatments or dose change) within previous 3 months~* HbA1c \> 58mmol/mol (7.5%) and ≤110mmol/mol (12.2%) - confirmed at screening visit~* eGFR ≥ 60mls/min/1.73m² - confirmed at screening visit~* Able and willing to give informed consent~Exclusion Criteria:~* Changes in glucose-lowering therapy or dose within last 3 months~* HbA1c ≤ 58mmol/mol (7.5%) or \>110mmol/mol (12.2%)~* eGFR \<60mls/min/1.73m².~* Diabetes duration \<12 months~* ALT \>2.5 x upper limit of the assay normal range or known liver disease, specifically \>30 μmol/L that is associated with other evidence of liver failure.~* Insulin treated within the last 12 months~* Limb ischaemia shown by absence of both pulses in one or both feet.~* Currently treated with corticosteroids~* Currently treated with rifampicin, gemfibrozil, phenytoin and carbamazepine~* Active infection (any infection requiring antibiotics at present)~* Foot ulcer requiring antibiotics within previous three months~* Recent (within 3 months) significant surgery or planned surgery (excluding minor procedures)~* Acute cardiovascular episode (angina, myocardial infarction, stroke, transient ischemic episode) occurring within the previous 3 months~* History of heart failure~* Current use of loop diuretic therapy (Furosemide or Bumetanide)~* History of bladder carcinoma~* Current/ongoing investigation for macroscopic haematuria~* History of Diabetic Ketoacidosis~* History of pancreatitis~* Pregnant, breastfeeding or planning a pregnancy over the study period~* Concurrent Participation on another Clinical Trial of an Investigational Medicinal Product, where the IMP is currently being taken, or without sufficient washout period\* and without consultation with the CTIMP research team.~* Unable or unwilling to give informed consent~  * Sufficient washout period = five times the half-life of the IMP / potential IMP if involving a placebo / longest half-life if a trial includes more than one drug

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin - DPP4i (Type: EXPERIMENTAL): None
- Canagliflozin - SGLT2i (Type: EXPERIMENTAL): None
- Pioglitazone - TZD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).